Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14669268 | 1.00 | OGA (0.41) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL9314127 | 1.00 | OGA (0.41) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL9314131 | 1.00 | OGA (0.41) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL9314136 | 1.00 | OGA (0.41) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL20193825 | 0.83 | CYP2C9 (0.33) | OGAMAPK1ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL9314303 | 0.81 | LGALS8 (0.42) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL9314298 | 0.81 | LGALS8 (0.42) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL9314309 | 0.81 | LGALS8 (0.42) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL24917518 | 0.79 | OGA (0.36) | OGAMAPK1ALDH1A1THRBCD69 | |
| SCHEMBL18978073 | 0.79 | OGA (0.42) | OGALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | OGA 225/4885MAPK1 4597/4885ALDH1A1 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.